Genome & Company

Genome & Company

Contact

Genome & Company
B-8F Silicon Park, 35 Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13486

Map

Consent to collection and use of personal information (Required)

Genome & Company (the ”Company”) regards the protection of personal information of our users very important, and complies with relevant laws, including the Personal Information Protection Act and the Act on Expansion of Dissemination and Promotion of Utilization of Information System. The Company hereby informs the purpose and method of using the personal information provided by our users through the Company’s website, and what measures are taken to protect the personal information. If the Company revises any of this Private Policy, it will be notified through the notices on the Company’s website (or individually notified).

1. Items of Personal Information Collected and the Collection Method

The Company collects the following personal information to operate its Contact Service via the Company’s website (whereby the users can make general inquires, inquiry for business development, IR inquiry, media inquiry, etc.).
- Essential Information: name, e-mail address, phone number, organization, content of inquiry
- Collection method: The Company collects the personal information through the inquiries submitted via the Contact Bulletin Board on the Company’s website.

  You have the right to refuse the ‘collection of essential information’ as well as the ‘collection of optional information’. If you refuse the collection of essential information, however, you may be restricted for using the Contact Service.

The following information may be automatically generated and collected in the process of using the website.
- IP Address, cookie, date and time of visit, records of service use

2. Purpose of Collecting Personal Information

The Company uses the collected personal information for the following purposes.
- Personal verification, personal identification, delivery of inquiries and notification of results (answers and responses), etc. related to the use of Contact Service

3. Processing of Personal Information and Retention Period

In principle, the collected personal information is destroyed without any delay after achieving the purpose of collecting and using personal information. However, the Company may keep users’ information for a certain period of time as required by relevant laws.
- Retained information: personal information submitted with the inquiry, content of the inquiry, and ensuing responses
- Relevant Law: Act on the Consumer Protection in Electronic Commerce, etc.
- Retention Period: three years (records related to resolution of consumer complaints or disputes)

4. Destruction of Personal Informatio

In principle, the information is destroyed without any delay after achieving the purpose of collecting and using personal information. The procedure and method of destruction are as follows.

1) Procedure
The personal information submitted is transferred to a separate database (in case of paper, separate cabinet) after achieving the purpose and kept for a certain period of time according to the internal policy and other relevant laws, before it is destroyed. The personal information transferred to separate database shall not be used any other purposes other than for keeping in accordance with laws.

  2) Destruction Method
Personal information saved in the form of electronic file shall be deleted by using technical method that cannot reproduce the records. Personal information printed in the paper shall be destroyed by shredding with a shredder or incinerating it.

5. Consignment of Personal Information Processing

The Company does not consign personal information to a third party. If consignment occurs in the future, it shall be notified through website and the contents of this Privacy Policy shall be updated.

6. Rights of Users and Their Legal Representatives

Users and their legal representative (for the users below the age of 14) may make an inquiry related to or request deletion or modification of their own personal information. In this case, please contact the Company’s Data Protection Manager (see Section 7 of this Privacy Policy) in writing, by phone, or by e-mail so that we can take measures without any delay after verifying your identification.

In case users request the correction of any errors in personal information, we shall not use or provide the personal information until such correction is made. In addition, in case incorrect personal information is already provided to a third party, we will notify the third party the result of correction without delay.

The Company processes and destroys personal information at the request of users or their legal representatives in accordance with Section ‘3. Processing of Personal Information and Retention Period’ and Section ‘4. Destruction of Personal Information’, and such information shall not be opened or used for any other purposes.

7. Information on Data Protection Officer and Manager

The Company designates data protection officer and manager for managing personal information as follows to protect users’ personal information related to inquiries.

Data Protection Officer
Name: Seo Yeong-jin
Department: Business management
Position: Vice-president
Telephone: 031-620-0150
Email: youngjin.seo@genomecom.co.kr

  Data Protection Manager
Name: Seol Su-gi
Department: PR team
Position: Team Lead
Telephone: 070-4821-3840
Email: sugi@genomecom.co.kr

You can submit to the personnel above any inquiries related to your personal information submitted to the Company while using our web service. The Company will quickly provide sufficient responses to your inquiries.

Please contact the below agencies if you need report or counseling for any infringement of personal data privacy.

- Personal Information Infringement Report Center (privacy.kisa.or.kr / 118 without area code)
- Personal Information Dispute Mediation Committee (kopico.go.kr / 1833-6972)
- Cyber Investigation Department, Supreme Prosecutor’s Office (www.spo.go.kr / 1301 without area code)
- Cyber Bureau of the National Police Agency (http://cyberbureau.police.go.kr / 182 without area code)

8. Notification

We will notify users any additions, deletions, and modification on the current Privacy Policy in advance through ‘Notice’ on the Company’s website.

9. Other Websites

We inform you that any collection of personal information by other websites which may be hyperlinked on the Company’s website is not the subject of this Privacy Policy.

Press Release

[Press Release] Scioto Biosciences, Inc announces first patient dosed …

Scioto Biosciences, Inc announces first patient dosed in Phase Ib study in patients diagnosed with Autistic Disorder

Scioto Biosciences, Inc.

August, 18, 2021

 

Scioto Biosciences, Inc. (Indianapolis, IN) announced the beginning of their Phase Ib clinical trial for the lead investigational product SB-121.  The first patient was randomized and started dosing in mid-August.  Scioto is an innovation-driven biotechnology company focused on developing a novel microbiome platform called Activated Bacterial Therapeutics (ABT).  SB-121 is the first ever ABT to be tested in the clinic. 

The Phase Ib trial is being conducted in patients diagnosed with Autistic Disorder (AD) between the ages of 15 and 45.  The study is a multiple dose, double-blinded, placebo-controlled trial.  The primary objective is to assess the safety and tolerability of SB-121.  The secondary objectives include assessment of the impact of SB-121 on measures of AD. 

“This study is an important milestone in our understanding of how the microbiome effects the gut-brain axis in patients with AD.  It will significantly advance our efforts to potentially develop SB-121 as a therapy for patients with AD by providing critical safety data in this patient population,” said Joe Trebley, PhD, CEO of Scioto.

Scioto announced in August 2020 the raising of a Series B financing from Genome and Company (G&C).  G&C (KRX: 314130) began trading on the KOSDAQ, the Korean counterpart to the US NASDAQ, in Dec 2020.  G&C is one of the leading microbiome companies in the world. Scioto has laboratory space at the Indiana Center for Biomedical Innovation in Indianapolis and executive offices in Fishers, IN.  The clinical trial is being performed at Cincinnati Children’s Hospital Medical Center (CCHMC) in Cincinnati, OH.

“We are very excited to achieve this milestone with our partners at Scioto, “said Jisoo Pae, MD, founder and CEO of G&C.  “We think SB-121 can potentially make a big impact in the lives of patients diagnosed with AD.  We look forward to reviewing the data and further exploring the possibilities of SB-121 and Scioto’s ABT platform.”

“G&C has been the ideal partner in helping us take Scioto from a pre-clinical to clinical stage company.  The G&C and the Scioto teams have been working collaboratively, and we are looking forward to developing SB-121 for other indications.  We are off to a great start,” added Trebley.

About Scioto Biosciences

Based in Indianapolis, Scioto Biosciences is a clinical stage company developing innovative therapies devoted to having a transformative impact on the delivery of live bacterial therapeutics (LBTs). The Scioto Activated Bacterial Therapeutic (ABT) Platform has the potential to enhance efficacy wherever LBTs are used such as gastrointestinal health, diabetes, neurological disorders, alternatives to in-feed antibiotics (in livestock) and others.  For more information, visit http://sciotobiosciences.com/

 About Genome & Company

Genome & Company is a publicly traded (KRX: 314130), clinical-stage biotechnology company based in Seongnam, Republic of Korea that focuses on discovering and developing the next waves of innovative therapeutics in immuno-oncology through diverse modalities of microbiome, novel target immune checkpoint inhibitors and fusion proteins to fulfill the unmet needs of cancer patients. For more information, visit http://genomecom.co.kr/

 

 
NEXT [Press Release] Scioto Biosciences, a Genome & Company affiliate, publish the protective results of ABT™platform